For research in areas such as Parkinson’s disease, digital endpoints may soon be used as primary endpoints, allowing for in-home clinical trials to be conducted over longer periods of time, says CRO.
Apptomics is working with BBK and Biotaware to develop the remote health-monitoring platform, which recently served as a digital biomarker to evaluate treatment effects as part of an essential tremor clinical trial.